Therefore, like USP7, accumulating evidence indicates that USP22 also represents a promising target for cancer therapy, and USP22 knockdown markedly decreases cancer growth, induces apoptosis, and sensitizes cancer cells to chemo-radio and immune therapies [17, 34–36]. This evidence concerns the gene USP22 and cancer.